Cipla
Cipla Limited, a leading global pharmaceutical company headquartered in India, has been a pioneer in the healthcare industry since its establishment in 1935. With a strong presence in over 80 countries, Cipla focuses on developing a wide range of generic medicines, active pharmaceutical ingredients (APIs), and over-the-counter products. Renowned for its commitment to affordable healthcare, Cipla has made significant strides in areas such as respiratory, cardiovascular, and anti-retroviral therapies. The company is distinguished by its innovative approach to drug development and its robust pipeline of products, which cater to diverse therapeutic needs. Cipla's market position is bolstered by its extensive distribution network and strategic partnerships, making it a trusted name in the pharmaceutical sector. With numerous accolades for its contributions to global health, Cipla continues to lead the way in providing high-quality, accessible medicines.
DitchCarbon Score
How does Cipla's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cipla's score of 42 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cipla's reported carbon emissions
Cipla, headquartered in India, has made significant strides in addressing its carbon emissions, with a commitment to achieving carbon neutrality by December 2025. In 2023, the company reported emissions of approximately 35831000 kg CO2e for Scope 1, 195777000 kg CO2e for Scope 2, and a substantial 4105383000 kg CO2e for Scope 3 emissions. This reflects a comprehensive approach to emissions management, covering direct emissions (Scope 1), indirect emissions from energy consumption (Scope 2), and other indirect emissions (Scope 3). In recent years, Cipla has focused on reducing its Scope 1 and Scope 2 emissions, with specific targets set for its manufacturing operations in India. The company aims to enhance energy efficiency and increase the use of renewable energy sources, including electricity and biofuels, as part of its long-term strategy. Notably, in 2021, Cipla's Scope 1 emissions were reported at 41617000 kg CO2e, while Scope 2 emissions reached 201676000 kg CO2e, indicating a proactive approach to emissions reduction. Cipla's commitment to sustainability is further underscored by its strategic pathways developed to meet its carbon neutrality goals, which include improving operational energy efficiency and transitioning to renewable energy sources. As the company progresses towards its 2025 target, it continues to align its operations with industry standards for climate action, demonstrating a robust commitment to mitigating climate change impacts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 236,358,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 55,013,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | 00,000,000 | - | - | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cipla is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
